CA1225930A - Anticorps monoclonaux conjugues avec des chelates metalliques - Google Patents

Anticorps monoclonaux conjugues avec des chelates metalliques

Info

Publication number: CA1225930A
Authority: CA; Canada
Prior art keywords: chelate; solution; metal; radiometal; monoclonal antibodies
Prior art date: 1982-06-07
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA000429760A

Other languages

English (en)

Inventor

Otto A. Gansow

Mette Strand

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-06-07

Filing date

1983-06-06

Publication date

1987-08-25

1982-06-07 Priority claimed from US06/386,110 external-priority patent/US4472509A/en

1982-06-07 Priority claimed from US06/386,109 external-priority patent/US4454106A/en

1983-06-06 Application filed by Individual filed Critical Individual

1987-08-25 Application granted granted Critical

1987-08-25 Publication of CA1225930A publication Critical patent/CA1225930A/fr

Status Expired legal-status Critical Current

Links

239000013522 chelant Substances 0.000 title claims abstract description 111
229910052751 metal Inorganic materials 0.000 title claims abstract description 92
239000002184 metal Substances 0.000 title claims abstract description 92
238000000034 method Methods 0.000 claims abstract description 36
239000000243 solution Substances 0.000 claims description 78
QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims description 35
239000011347 resin Substances 0.000 claims description 35
229920005989 resin Polymers 0.000 claims description 35
150000002500 ions Chemical class 0.000 claims description 26
229960003330 pentetic acid Drugs 0.000 claims description 26
239000002253 acid Substances 0.000 claims description 25
230000000694 effects Effects 0.000 claims description 17
239000007864 aqueous solution Substances 0.000 claims description 16
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 14
239000011159 matrix material Substances 0.000 claims description 12
230000004071 biological effect Effects 0.000 claims description 11
239000000872 buffer Substances 0.000 claims description 10
239000003729 cation exchange resin Substances 0.000 claims description 10
150000002148 esters Chemical class 0.000 claims description 10
150000003839 salts Chemical class 0.000 claims description 10
238000004513 sizing Methods 0.000 claims description 10
239000003456 ion exchange resin Substances 0.000 claims description 9
229920003303 ion-exchange polymer Polymers 0.000 claims description 9
150000008064 anhydrides Chemical class 0.000 claims description 7
239000003957 anion exchange resin Substances 0.000 claims description 6
230000001413 cellular effect Effects 0.000 claims description 6
239000003960 organic solvent Substances 0.000 claims description 5
238000011282 treatment Methods 0.000 claims description 4
YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 claims description 3
-1 amine diethylenetriaminepentaacetic acid salt Chemical class 0.000 claims description 2
229960004424 carbon dioxide Drugs 0.000 claims 1
239000007795 chemical reaction product Substances 0.000 claims 1
230000005855 radiation Effects 0.000 abstract description 14
230000001225 therapeutic effect Effects 0.000 abstract description 5
238000004519 manufacturing process Methods 0.000 abstract description 2
210000004027 cell Anatomy 0.000 description 26
238000006243 chemical reaction Methods 0.000 description 24
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 21
239000002245 particle Substances 0.000 description 17
150000002739 metals Chemical class 0.000 description 16
210000000952 spleen Anatomy 0.000 description 15
241000699670 Mus sp. Species 0.000 description 14
210000004185 liver Anatomy 0.000 description 14
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical group CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 13
150000007513 acids Chemical class 0.000 description 11
102000004169 proteins and genes Human genes 0.000 description 10
108090000623 proteins and genes Proteins 0.000 description 10
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
206010028980 Neoplasm Diseases 0.000 description 9
150000001412 amines Chemical class 0.000 description 9
210000004369 blood Anatomy 0.000 description 9
239000008280 blood Substances 0.000 description 9
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
238000000502 dialysis Methods 0.000 description 9
239000000499 gel Substances 0.000 description 9
210000000056 organ Anatomy 0.000 description 9
238000000746 purification Methods 0.000 description 9
239000011780 sodium chloride Substances 0.000 description 9
210000001519 tissue Anatomy 0.000 description 9
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
241000699666 Mus <mouse, genus> Species 0.000 description 8
229910021645 metal ion Inorganic materials 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
239000000427 antigen Substances 0.000 description 6
108091007433 antigens Proteins 0.000 description 6
102000036639 antigens Human genes 0.000 description 6
JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 6
230000030833 cell death Effects 0.000 description 6
238000001727 in vivo Methods 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
210000003734 kidney Anatomy 0.000 description 6
239000003446 ligand Substances 0.000 description 6
238000008416 Ferritin Methods 0.000 description 5
JCXGWMGPZLAOME-AKLPVKDBSA-N bismuth-212 Chemical compound [212Bi] JCXGWMGPZLAOME-AKLPVKDBSA-N 0.000 description 5
239000000047 product Substances 0.000 description 5
230000002285 radioactive effect Effects 0.000 description 5
210000002784 stomach Anatomy 0.000 description 5
238000012360 testing method Methods 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
102000008857 Ferritin Human genes 0.000 description 4
108050000784 Ferritin Proteins 0.000 description 4
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
229920005654 Sephadex Polymers 0.000 description 4
239000012507 Sephadex™ Substances 0.000 description 4
230000002378 acidificating effect Effects 0.000 description 4
235000010323 ascorbic acid Nutrition 0.000 description 4
239000011668 ascorbic acid Substances 0.000 description 4
230000009920 chelation Effects 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
125000000524 functional group Chemical group 0.000 description 4
210000004408 hybridoma Anatomy 0.000 description 4
229940127121 immunoconjugate Drugs 0.000 description 4
239000011541 reaction mixture Substances 0.000 description 4
230000000717 retained effect Effects 0.000 description 4
239000000126 substance Substances 0.000 description 4
206010006187 Breast cancer Diseases 0.000 description 3
208000026310 Breast neoplasm Diseases 0.000 description 3
108060003951 Immunoglobulin Proteins 0.000 description 3
206010035226 Plasma cell myeloma Diseases 0.000 description 3
239000004793 Polystyrene Substances 0.000 description 3
230000002411 adverse Effects 0.000 description 3
230000002776 aggregation Effects 0.000 description 3
238000004220 aggregation Methods 0.000 description 3
229960005070 ascorbic acid Drugs 0.000 description 3
229910052797 bismuth Inorganic materials 0.000 description 3
229940023913 cation exchange resins Drugs 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
230000021615 conjugation Effects 0.000 description 3
231100000433 cytotoxic Toxicity 0.000 description 3
230000001472 cytotoxic effect Effects 0.000 description 3
238000000354 decomposition reaction Methods 0.000 description 3
239000011521 glass Substances 0.000 description 3
102000018358 immunoglobulin Human genes 0.000 description 3
229940072221 immunoglobulins Drugs 0.000 description 3
230000004807 localization Effects 0.000 description 3
201000000050 myeloid neoplasm Diseases 0.000 description 3
229920001467 poly(styrenesulfonates) Polymers 0.000 description 3
229920002223 polystyrene Polymers 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
230000008569 process Effects 0.000 description 3
238000000926 separation method Methods 0.000 description 3
229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
235000017557 sodium bicarbonate Nutrition 0.000 description 3
239000001509 sodium citrate Substances 0.000 description 3
210000004989 spleen cell Anatomy 0.000 description 3
210000004881 tumor cell Anatomy 0.000 description 3
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
102000014914 Carrier Proteins Human genes 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical class OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
102000004338 Transferrin Human genes 0.000 description 2
108090000901 Transferrin Proteins 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
239000006227 byproduct Substances 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
229920001429 chelating resin Polymers 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
239000012141 concentrate Substances 0.000 description 2
229920001577 copolymer Polymers 0.000 description 2
150000002170 ethers Chemical class 0.000 description 2
230000004927 fusion Effects 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
238000003384 imaging method Methods 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
XMBWDFGMSWQBCA-RNFDNDRNSA-M iodine-131(1-) Chemical compound [131I-] XMBWDFGMSWQBCA-RNFDNDRNSA-M 0.000 description 2
238000005342 ion exchange Methods 0.000 description 2
230000005865 ionizing radiation Effects 0.000 description 2
229910052742 iron Inorganic materials 0.000 description 2
WABPQHHGFIMREM-OUBTZVSYSA-N lead-208 Chemical compound [208Pb] WABPQHHGFIMREM-OUBTZVSYSA-N 0.000 description 2
239000007788 liquid Substances 0.000 description 2
210000000865 mononuclear phagocyte system Anatomy 0.000 description 2
210000004940 nucleus Anatomy 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
HZEBHPIOVYHPMT-AKLPVKDBSA-N polonium-212 atom Chemical compound [212Po] HZEBHPIOVYHPMT-AKLPVKDBSA-N 0.000 description 2
229920000768 polyamine Polymers 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
229920005990 polystyrene resin Polymers 0.000 description 2
238000001959 radiotherapy Methods 0.000 description 2
230000035484 reaction time Effects 0.000 description 2
239000007787 solid Substances 0.000 description 2
241000894007 species Species 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
BKVIYDNLLOSFOA-RNFDNDRNSA-N thallium-208 Chemical compound [208Tl] BKVIYDNLLOSFOA-RNFDNDRNSA-N 0.000 description 2
239000012581 transferrin Substances 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
229940038773 trisodium citrate Drugs 0.000 description 2
CXENHBSYCFFKJS-OXYODPPFSA-N (Z,E)-alpha-farnesene Chemical compound CC(C)=CCC\C(C)=C\C\C=C(\C)C=C CXENHBSYCFFKJS-OXYODPPFSA-N 0.000 description 1
UUFQTNFCRMXOAE-UHFFFAOYSA-N 1-methylmethylene Chemical compound C[CH] UUFQTNFCRMXOAE-UHFFFAOYSA-N 0.000 description 1
PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
WYMDDFRYORANCC-UHFFFAOYSA-N 2-[[3-[bis(carboxymethyl)amino]-2-hydroxypropyl]-(carboxymethyl)amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)CN(CC(O)=O)CC(O)=O WYMDDFRYORANCC-UHFFFAOYSA-N 0.000 description 1
JUIKUQOUMZUFQT-UHFFFAOYSA-N 2-bromoacetamide Chemical class NC(=O)CBr JUIKUQOUMZUFQT-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
101100076790 Bacillus subtilis (strain 168) metP gene Proteins 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical class NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical class NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
GUTLYIVDDKVIGB-OUBTZVSYSA-N Cobalt-60 Chemical compound [60Co] GUTLYIVDDKVIGB-OUBTZVSYSA-N 0.000 description 1
101800001467 Envelope glycoprotein E2 Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
241000726306 Irus Species 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
101100409194 Rattus norvegicus Ppargc1b gene Proteins 0.000 description 1
101800001271 Surface protein Proteins 0.000 description 1
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
239000011149 active material Substances 0.000 description 1
125000002015 acyclic group Chemical group 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
238000005349 anion exchange Methods 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
150000001540 azides Chemical class 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
JCXGWMGPZLAOME-NJFSPNSNSA-N bismuth-211 Chemical compound [211Bi] JCXGWMGPZLAOME-NJFSPNSNSA-N 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
125000002843 carboxylic acid group Chemical group 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000005341 cation exchange Methods 0.000 description 1
230000005779 cell damage Effects 0.000 description 1
208000037887 cell injury Diseases 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
210000003855 cell nucleus Anatomy 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
AOGYCOYQMAVAFD-UHFFFAOYSA-N chlorocarbonic acid Chemical compound OC(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-N 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000001268 conjugating effect Effects 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000011443 conventional therapy Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000007822 coupling agent Substances 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
239000002739 cryptand Substances 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
239000000032 diagnostic agent Substances 0.000 description 1
229940039227 diagnostic agent Drugs 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000010828 elution Methods 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000011347 external beam therapy Methods 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
239000012467 final product Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
238000005227 gel permeation chromatography Methods 0.000 description 1
230000005484 gravity Effects 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000011258 immunoradiotherapy Methods 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000011503 in vivo imaging Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
229910052738 indium Inorganic materials 0.000 description 1
APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
PSCMQHVBLHHWTO-UHFFFAOYSA-K indium(iii) chloride Chemical compound Cl[In](Cl)Cl PSCMQHVBLHHWTO-UHFFFAOYSA-K 0.000 description 1
APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 1
229940055742 indium-111 Drugs 0.000 description 1
238000013101 initial test Methods 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical class NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
150000008040 ionic compounds Chemical class 0.000 description 1
238000002372 labelling Methods 0.000 description 1
238000011005 laboratory method Methods 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
230000007774 longterm Effects 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
239000002609 medium Substances 0.000 description 1
239000000203 mixture Substances 0.000 description 1
229910052755 nonmetal Inorganic materials 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
239000013110 organic ligand Substances 0.000 description 1
230000037361 pathway Effects 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
150000002989 phenols Chemical class 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000003495 polar organic solvent Substances 0.000 description 1
229920000570 polyether Polymers 0.000 description 1
230000000379 polymerizing effect Effects 0.000 description 1
229920006295 polythiol Polymers 0.000 description 1
150000004032 porphyrins Chemical class 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
239000012460 protein solution Substances 0.000 description 1
JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
239000010453 quartz Substances 0.000 description 1
125000001453 quaternary ammonium group Chemical group 0.000 description 1
230000000191 radiation effect Effects 0.000 description 1
239000012857 radioactive material Substances 0.000 description 1
230000000693 radiobiological effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
229910052706 scandium Inorganic materials 0.000 description 1
SIXSYDAISGFNSX-UHFFFAOYSA-N scandium atom Chemical compound [Sc] SIXSYDAISGFNSX-UHFFFAOYSA-N 0.000 description 1
238000003345 scintillation counting Methods 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
GROMGGTZECPEKN-UHFFFAOYSA-N sodium metatitanate Chemical compound [Na+].[Na+].[O-][Ti](=O)O[Ti](=O)O[Ti]([O-])=O GROMGGTZECPEKN-UHFFFAOYSA-N 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
239000012265 solid product Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical class O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000008685 targeting Effects 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
150000003573 thiols Chemical class 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
238000012546 transfer Methods 0.000 description 1
210000003932 urinary bladder Anatomy 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
239000011800 void material Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Virology (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Optics & Photonics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Hematology (AREA)
Cell Biology (AREA)
Physics & Mathematics (AREA)
Oncology (AREA)
Epidemiology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Radiation-Therapy Devices (AREA)

CA000429760A 1982-06-07 1983-06-06 Anticorps monoclonaux conjugues avec des chelates metalliques Expired CA1225930A (fr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US386,110		1982-06-07
US06/386,110 US4472509A (en)	1982-06-07	1982-06-07	Metal chelate conjugated monoclonal antibodies
US06/386,109 US4454106A (en)	1982-06-07	1982-06-07	Use of metal chelate conjugated monoclonal antibodies
US386,109		1989-07-28

Publications (1)

Publication Number	Publication Date
CA1225930A true CA1225930A (fr)	1987-08-25

Family

ID=27011278

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000429760A Expired CA1225930A (fr)	1982-06-07	1983-06-06	Anticorps monoclonaux conjugues avec des chelates metalliques

Country Status (5)

Country	Link
JP (1)	JP2599705B2 (fr)
CA (1)	CA1225930A (fr)
DE (1)	DE3320560A1 (fr)
FR (1)	FR2527928B1 (fr)
GB (1)	GB2122641B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4707352A (en) *	1984-01-30	1987-11-17	Enzo Biochem, Inc.	Method of radioactively labeling diagnostic and therapeutic agents containing a chelating group
CA1260827A (fr) *	1984-08-31	1989-09-26	Richard C. Siegel	Complexes anticorps - ions metalliques
US5393512A (en) *	1985-01-14	1995-02-28	Vanderheyden; Jean-Luc	Stable therapeutic radionuclide compositions and methods for preparation thereof
US4824986A (en) *	1985-04-26	1989-04-25	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Metal chelate protein conjugate
ATE89743T1 (de) *	1986-08-18	1993-06-15	Dow Chemical Co	Conjugate dichter sterne.
AU619218B2 (en) *	1987-11-06	1992-01-23	Abbott Laboratories	Methods and materials for the preparation of metal labelled antibody solutions
JPH01176000A (ja) *	1987-12-30	1989-07-12	Nippon Mejifuijitsukusu Kk	放射性医薬品とその調製用高分子化合物
US5972656A (en) *	1989-03-14	1999-10-26	Bionebraska, Inc.	Mercury binding polypeptides and nucleotides coding therefore
US5639624A (en) *	1989-03-14	1997-06-17	Board Of Regents Of The University Of Nebraska	Monoclonal antibodies specific for metallic cations and method therefor
WO1991004057A1 (fr) *	1989-09-22	1991-04-04	Neorx Corporation	Compositions de radionuclides therapeutiques stables et leurs procedes de preparation
US5244816A (en) *	1989-10-11	1993-09-14	Akzo N.V.	Method for purifying chelator conjugated compounds
CA2100709C (fr) *	1992-07-27	2004-03-16	Maurits W. Geerlings	Methode et moyens pour une therapie ciblee
US6111079A (en) *	1995-06-05	2000-08-29	Bionebraska, Inc.	Lead binding polypeptides and nucleotides coding therefore
ATE223237T1 (de) *	1996-11-15	2002-09-15	Euratom	Ex-corpore verfahren zur behändlung von blut- zellen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH583036A5 (fr) *	1972-05-12	1976-12-31	Hoffmann La Roche
JPS5857149B2 (ja) *	1975-12-25	1983-12-19	スギウラマモル	エル − アミノサンサンカコウソノセイセイホウ
US4311688A (en) *	1979-10-29	1982-01-19	Serono Laboratories Inc.	Composition and method for cancer detection in humans
US4421735A (en) *	1980-04-17	1983-12-20	The Massachusetts General Hospital	Radiolabeled diagnostic compositions and method for making the same
FR2515046B1 (fr) *	1981-10-27	1985-11-29	Hybritech Inc	Anticorps monoclonaux marques par un radionucleide et leur application a la visualisation d'une tumeur
US4666697A (en) *	1982-12-08	1987-05-19	Nihon Medi-Physics Co., Ltd.	Radioactive diagnostic agent

1983
- 1983-06-06 CA CA000429760A patent/CA1225930A/fr not_active Expired
- 1983-06-06 GB GB08315483A patent/GB2122641B/en not_active Expired
- 1983-06-07 FR FR8309437A patent/FR2527928B1/fr not_active Expired
- 1983-06-07 DE DE19833320560 patent/DE3320560A1/de active Granted
- 1983-06-07 JP JP58101593A patent/JP2599705B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
GB8315483D0 (en)	1983-07-13
FR2527928B1 (fr)	1989-09-22
JP2599705B2 (ja)	1997-04-16
JPS5946227A (ja)	1984-03-15
GB2122641B (en)	1986-08-06
DE3320560A1 (de)	1984-02-09
GB2122641A (en)	1984-01-18
FR2527928A1 (fr)	1983-12-09
DE3320560C2 (fr)	1993-09-16

Legal Events

Date	Code	Title	Description
2004-08-25	MKEX	Expiry

Publication	Publication Date	Title
US4472509A (en)	1984-09-18	Metal chelate conjugated monoclonal antibodies
US4454106A (en)	1984-06-12	Use of metal chelate conjugated monoclonal antibodies
US4741900A (en)	1988-05-03	Antibody-metal ion complexes
CA2158054C (fr)	2001-05-15	Conjugues de proteines et de ligands bifonctionnels
EP0173629B1 (fr)	1992-06-10	Complexes d'ions métalliques conjugés avec des anticorps
US4634586A (en)	1987-01-06	Reagent and method for radioimaging leukocytes
CA1225930A (fr)	1987-08-25	Anticorps monoclonaux conjugues avec des chelates metalliques
AU638127B2 (en)	1993-06-17	A bifunctional dtpa-type ligand
KR0162259B1 (ko)	1998-12-01	감염성 병변 및 염증성 병변을 검출 및 치료하기 위한 키메라 항체
AU649079B2 (en)	1994-05-12	Modified antibodies with controlled clearance time
AU611105B2 (en)	1991-06-06	Polysubstituted diethylenetriamine pentacetic acid (dtpa) chelating agents
US5099069A (en)	1992-03-24	Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
JPH03500419A (ja)	1991-01-31	多特異抗白血球結合体及び哺乳動物用非経口的注射剤
Appelbaum et al.	1989	Antibody-radionuclide conjugates as part of a myeloablative preparative regimen for marrow transplantation
US5380513A (en)	1995-01-10	Methods for reducing non-target retention of immunoconjugates and metabolites thereof
US6696551B1 (en)	2004-02-24	225Ac-HEHA and related compounds, methods of synthesis and methods of use
WO1992011039A1 (fr)	1992-07-09	Agents de chelation a base de tricatechol derives
Gansow et al.	1984	Metal chelate conjugated monoclonal antibodies, wherein the metal is an α emitter
WO1993009816A1 (fr)	1993-05-27	Procede de diagnostic et de traitement du cancer
Zoghbi et al.	1985	A modified procedure for rapid labelling of low concentrations of bioactive proteins with indium-111
WO2000059896A1 (fr)	2000-10-12	225ac-heha et composes, procedes de synthese et procedes d'utilisation correspondants
USH735H (en)	1990-02-06	Lead-203 as a label for radioimaging
Endo et al.	1984	Tumor imaging by monoclonal antibodies labeled with radioactive metal ions
Fawwaz et al.	1986	The biodistribution of radiolabeled antilymphocyte monoclonal antibody in the rat